Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-cash Items (2022 - 2026)

Immunome filings provide 5 years of Non-cash Items readings, the most recent being $81.7 million for Q1 2026.

  • On a quarterly basis, Non-cash Items rose 2192.6% to $81.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $81.7 million, a 2192.6% increase, with the full-year FY2025 number at $180.7 million, up 428.13% from a year prior.
  • Non-cash Items hit $81.7 million in Q1 2026 for Immunome, down from $180.7 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $180.7 million in Q4 2025 to a low of $1.2 million in Q4 2022.
  • Median Non-cash Items over the past 5 years was $19.1 million (2024), compared with a mean of $45.6 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 10582.7% in 2024 and later tumbled 97.56% in 2025.
  • Immunome's Non-cash Items stood at $1.2 million in 2022, then surged by 3560.68% to $45.4 million in 2023, then fell by 24.58% to $34.2 million in 2024, then soared by 428.13% to $180.7 million in 2025, then tumbled by 54.78% to $81.7 million in 2026.
  • The last three reported values for Non-cash Items were $81.7 million (Q1 2026), $180.7 million (Q4 2025), and $87.4 million (Q3 2025) per Business Quant data.